Advance in Targeted Immunotherapy for Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) is a serious and deadly complication of patients, who undergo hematopoietic stem cell transplantation (HSCT). Despite prophylactic treatment with immunosuppressive agents, 20–80% of recipients develop acute GVHD after HSCT. And the incidence rates of chronic GVHD ran...
Main Authors: | Lingling Zhang, Jianhua Yu, Wei Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.01087/full |
Similar Items
-
Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
by: Yiyin Chen, et al.
Published: (2023-07-01) -
Graft-versus-host disease: Therapeutic prospects of improving the long-term post-transplant outcomes
by: Abdulaziz Umar Kurya, et al.
Published: (2022-12-01) -
A case of psoriasiform graft-versus-host disease
by: Jinping HUANG, et al.
Published: (2022-06-01) -
Extensive acute cutaneous graft versus host disease: A rare case report of survival
by: Prajwal Pudasaini, et al.
Published: (2023-06-01) -
Immune Ablation and Stem Cell Rescue in Two Pediatric Patients with Progressive Severe Chronic Graft-Versus-Host Disease
by: Jaspar Kloehn, et al.
Published: (2022-12-01)